JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies

Journal of Clinical Investigation

Volumn 128, Issue 7, 2018, Pages 3041-3052

  Montealegre Sanchez, Gina A ^a   Reinhardt, Adam ^b   Ramsey, Suzanne ^c   Wittkowski, Helmut ^d   Hashkes, Philip J ^e   Berkun, Yackov ^f   Schalm, Susanne ^g   Murias, Sara ^h   Dare, Jason A ⁱ   Brown, Diane ^j   Stone, Deborah L ^k   Gao, Ling ⁱ   Klausmeier, Thomas ^l   Foell, Dirk ^d   De Jesus, Adriana A ^a   Chapelle, Dawn C ^m   Kim, Hanna ^m   Dill, Samantha ^m   Colbert, Robert A ^m   Failla, Laura ^a   Kost, Bahar ^m   O’Brien, Michelle ^m   Reynolds, James C ⁿ   Folio, Les R ⁿ   Calvo, Katherine R ⁿ   Paul, Scott M ⁿ   Weir, Nargues ^o   Brofferio, Alessandra ^o   Soldatos, Ariane ^p   Biancotto, Angelique ^o   Cowen, Edward W ^m   Digiovanna, John J ^q   Gadina, Massimo ^m   Lipton, Andrew J ^r   Hadigan, Colleen ^a   Holland, Steven M ^a   Fontana, Joseph ^o   Alawad, Ahmad S ^s   Brown, Rebecca J ^s   Rother, Kristina I ^s   Heller, Theo ^s   Brooks, Kristina M ⁿ   Kumar, Parag ⁿ   Brooks, Stephen R ^m   Waldman, Meryl ^s   Singh, Harsharan K ^t   Nickeleit, Volker ^t   Silk, Maria ^u   Prakash, Apurva ^u   Janes, Jonathan M ^u   Ozen, Seza ^v   Wakim, Paul G ^w   Brogan, Paul A ^x   Macias, William L ^u   Goldbach Mansky, Raphaela ^a   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c IWK HEALTH CENTRE   (Canada)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e SHAARE ZEDEK MEDICAL CENTER   (Israel)

^f HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h HOSPITAL INFANTIL LA PAZ   (Spain)

ⁱ UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^j CHILDREN S HOSPITAL LOS ANGELES   (United States)

^k NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^l RILEY HOSPITAL FOR CHILDREN   (United States)

^m NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

ⁿ NATIONAL INSTITUTES OF HEALTH   (United States)

^o NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^p NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^q NATIONAL CANCER INSTITUTE   (United States)

^r WALTER REED ARMY MEDICAL CENTER   (United States)

^s NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^t UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^u ELI LILLY AND COMPANY   (United States)

^v HACETTEPE UNIVERSITY   (Turkey)

^w NATIONAL INSTITUTES OF HEALTH   (United States)

^x UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BARICITINIB; CORTICOSTEROID; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PREDNISONE; TRIACYLGLYCEROL; AZETIDINE DERIVATIVE; INTERFERON; JAK1 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE INHIBITOR; SULFONAMIDE;

ADOLESCENT; ADULT; ARTICLE; AUTOINFLAMMATORY DISEASE; AUTOINFLAMMATORY INTERFERONOPATHY; BACTEREMIA; BACTERIAL INFECTION; BONE AGE; BONE DENSITY; CELLULITIS; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CHILD; CHRONIC ATYPICAL NEUTROPHILIC DERMATOSIS WITH LIPODYSTROPHY AND ELEVATED TEMPERATURE; CLINICAL ARTICLE; CLINICAL OUTCOME; CLOSTRIDIUM DIFFICILE INFECTION; COMPASSIONATE USE; CONJUNCTIVITIS; CORTICOSTEROID THERAPY; DEVICE INFECTION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EPIDIDYMITIS; ERYTHROCYTE SEDIMENTATION RATE; EYE INFECTION; FEMALE; FOLLICULITIS; FORCED VITAL CAPACITY; GAIN OF FUNCTION MUTATION; GASTROENTERITIS; GASTROINTESTINAL INFECTION; GASTROINTESTINAL VIRAL INFECTION; GENITAL TRACT INFECTION; HEMOGLOBIN DETERMINATION; HERPES SIMPLEX; HERPES ZOSTER; HORDEOLUM; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; IN VITRO STUDY; INFLUENZA; INTERSTITIAL LUNG DISEASE; JAK-STAT SIGNALING; JOINT CONTRACTURE; KIDNEY FUNCTION; LIPODYSTROPHY; LIVEDO RETICULARIS; LIVER FUNCTION; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LYMPHOCYTE COUNT; MALE; METABOLIC SYNDROME X; MOLLUSCUM CONTAGIOSUM; MOUTH INFECTION; MYCOSIS; MYOSITIS; NAIL INFECTION; OSTEOMYELITIS; OTITIS MEDIA; PANNICULITIS; PARAINFLUENZA VIRUS INFECTION; PARONYCHIA; PATIENT CARE; PHARYNGITIS; PLATELET COUNT; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PYELONEPHRITIS; QUALITY OF LIFE; RASH; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RHINOVIRUS INFECTION; RISK ASSESSMENT; ROTAVIRUS INFECTION; SCHOOL CHILD; SINUSITIS; SKIN INFECTION; SKIN ULCER; STAPHYLOCOCCUS INFECTION; THRUSH; TINEA PEDIS; TOOTH ABSCESS; TOOTH INFECTION; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UROSEPSIS; VASCULITIS; VIRAL GASTROENTERITIS; VIREMIA; VIRUS INFECTION; VULVOVAGINITIS; WOUND INFECTION; YOUNG ADULT; CLINICAL TRIAL; COHORT ANALYSIS; ENZYMOLOGY; HEREDITARY PERIODIC FEVER; IMMUNOLOGY; INFANT; INFLAMMATION; METABOLISM; MULTICENTER STUDY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; AZETIDINES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COMPASSIONATE USE TRIALS; FEMALE; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; INFANT; INFLAMMATION; INTERFERONS; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE INHIBITORS; MALE; PROSPECTIVE STUDIES; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85048191394     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI98814     Document Type: Article

References (39)

1. de Jesus AA, Canna SW, Liu Y, Goldbach-Mansky R. Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling. Annu Rev Immunol. 2015;33:823–874.
2. Kim H, Sanchez GA, Goldbach-Mansky R. Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus. JMolMed. 2016;94(10):1111–1127.
3. Crow YJ. Type I interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci. 2011;1238:91–98.
4. Agarwal AK, et al. PSMB8 encoding the ß5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. Am J Hum Genet. 2010;87(6):866–872.
5. Arima K, et al. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc Natl Acad Sci U S A. 2011;108(36):14914–14919.
6. Kitamura A, et al. A mutation in the immunopro-teasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. J Clin Invest. 2011;121(10):4150–4160.
7. Liu Y, et al. Mutations in proteasome subunit ß type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum. 2012;64(3):895–907.
8. Brehm A, et al. Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. JClin Invest. 2015;125(11):4196–4211.
9. Liu Y, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014;371(6):507–518.
10. Jeremiah N, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest. 2014;124(12):5516–5520.
11. Melki I, et al. Disease-associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling. J Allergy Clin Immunol. 2017;140(2):543–552.e5.
12. Kim H, et al. Development of a validated interferon score using NanoString technology. J Interferon Cytokine Res. 2018;38(4):171–185.
13. Leonard WJ, O’Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol. 1998;16:293–322.
14. Igaz P, Tóth S, Falus A. Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice. Inflamm Res.2001;50(9):435–441.
15. Fridman JS, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. JImmunol. 2010;184(9):5298–5307.
16. Genovese MC, et al. Baricitinib in Patients with Refractory Rheumatoid Arthritis. N Engl J Med. 2016;374(13):1243–1252.
17. König N, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017;76(2):468–472.
18. Frémond ML, et al. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. J Allergy Clin Immunol. 2016;138(6):1752–1755.
19. Ramesh V, et al. Intracerebral large artery disease in Aicardi-Goutières syndrome implicates SAMHD1 in vascular homeostasis. Dev Med Child Neurol. 2010;52(8):725–732.
20. Argetsinger LS, et al. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell. 1993;74(2):237–244.
21. Metcalf D, et al. Gigantism in mice lacking suppressor of cytokine signalling-2. Nature. 2000;405(6790):1069–1073.
22. Otoda T, et al. Proteasome dysfunction mediates obesity-induced endoplasmic reticulum stress and insulin resistance in the liver. Diabetes. 2013;62(3):811–824.
23. Tanimoto A, Murata Y, Wang KY, Tsutsui M, Kohno K, Sasaguri Y. Monocyte chemoattractant protein-1 expression is enhanced by granulocyte-macrophage colony-stimulating factor via Jak2-Stat5 signaling and inhibited by atorvastatin in human monocytic U937 cells. JBiolChem. 2008;283(8):4643–4651.
24. Thorens B, Mermod JJ, Vassalli P. Phagocytosis and inflammatory stimuli induce GM-CSF mRNA in macrophages through posttranscrip-tional regulation. Cell. 1987;48(4):671–679.
25. Lendemans S, Rani M, Selbach C, Kreuzfelder E, Schade FU, Flohé S. GM-CSF priming of human monocytes is dependent on ERK1/2 activation. J Endotoxin Res. 2006;12(1):10–20.
26. Qian BZ, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222–225.
27. Xu LL, Warren MK, Rose WL, Gong W, Wang JM. Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro. JLeukocBiol. 1996;60(3):365–371.
28. Ivashkiv LB. Epigenetic regulation of macrophage polarization and function. Trends Immunol. 2013;34(5):216–223.
29. Mostafavi S, et al. Parsing the interferon transcriptional network and its disease associations. Cell. 2016;164(3):564–578.
30. Keystone EC, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 2015;74(2):333–340.
31. Taylor PC, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652–662.
32. Knowles WA. Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). Adv Exp Med Biol. 2006;577:19–45.
33. Rinaldo CH, Tylden GD, Sharma BN. The human polyomavirus BK (BKPyV): virological background and clinical implications. APMIS. 2013;121(8):728–745.
34. Polo C, Pérez JL, Mielnichuck A, Fedele CG, Niubò J, Tenorio A. Prevalence and patterns of polyomavirus urinary excretion in immunocom-petent adults and children. ClinMicrobiolInfect. 2004;10(7):640–644.
35. Rodero MP, Crow YJ. Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview. J Exp Med. 2016;213(12):2527–2538.
36. Kim H, et al. Pharmacokinetics, pharmacody-namics proposed dosing of the oral JAK1 JAK2 inhibitor baricitinib in pediatric young adult CANDLE SAVI Patients [published online ahead of print November 14, 2017]. Clin Phar-macol Ther. https://doi.org/10.1002/cpt.936.
37. Dixon WT. Simple proton spectroscopic imaging. Radiology. 1984;153(1):189–194.
38. Hamlett A, Ryan L, Serrano-Trespalacios P, Wolfinger R. Mixed models for assessing correlation in the presence of replication. J Air Waste Manag Assoc. 2003;53(4):442–450.
39. Ford ES, Ajani UA, Mokdad AH, National Health Nutrition Examination. The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. Diabetes Care. 2005;28(4):878–881.